This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Estrogens, primarily 17β-estradiol (E2), exert important modulatory functions in the CNS via both genomic and nongenomic (membrane-related) mechanisms. The sources of E2 for the brain include circulating E2 or testosterone secreted from peripheral tissue and rapidly gaining access to the CNS and E2 synthesized in neurons and glial cells. The effects of E2 are mediated by 2 types of estrogen receptors (ERs): ERα and ERβ. These receptors act as transcription factors mediating the genomic effects of E2 and as membrane-associated proteins that trigger rapid, nongenomic effects. Some of these rapid effects are also mediated by guanine-nucleotide binding (G)-protein-coupled receptors, including the G-protein-coupled ER-1 (GPER1, also known as GPR30). There is a cross-talk between the genomic and nongenomic effects of E2 via multiple phosphorylation cascades that also allow integration of E2 signaling with that of neurotransmitters and trophic factors. Many influences of E2 on neuronal development, dendritogenesis, synaptic plasticity, neuronal excitability, and neuroprotection involve these rapid, nongenomic membrane-related mechanisms. Via these effects, E2 may have a contributory role in epilepsy, migraine, and neurodegenerative disorders such as Alzheimer disease (AD) and Parkinson disease (PD). These subjects have been reviewed extensively.1–14
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
- © 2015 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
